非小细胞肺癌患者血清中MASP-2检测的临床价值  

Clinical value of serum MASP-2 detection in non-small cell lung cancer patients

作　　者：马尚 尹颜军[1] 张鑫桐 白万秋 荣长利[1] 时广利[1] MA Shang;YIN Yan-jun;ZHANG Xin-tong;BAI Wan-qiu;RONG Chang-li;SHI Guang-li(Department of Medical Laboratory,Beijing Tuberculosis Thoracic Tumor Institute/Beijing Chest Hospital Affiliated to Capital Medical University,Beijing 101149,China)

机构地区：[1]北京市结核病胸部肿瘤研究所/首都医科大学附属北京胸科医院,北京101149

出　　处：《临床肺科杂志》2020年第6期908-911,共4页Journal of Clinical Pulmonary Medicine

基　　金：北京市通州区高层次人才发展计划(No.YHLD2018023)。

摘　　要：目的通过检测血清中人甘露糖醇结合凝集素相关丝氨酸蛋白酶(MASP)-2在非小细胞肺癌(NSCLC)患者中的浓度水平,分析其作为NSCLC辅助诊断指标的临床价值。方法应用酶联免疫法和流式荧光法检测61名健康人、46例肺部良性疾病患者和139例NSCLC患者血清中MASP-2和细胞角蛋白19片段(Cyfra21-1)的浓度水平,分析联合检测血清MASP-2和Cyfra21-1在NSCLC辅助诊断中的临床意义。结果 NSCLC患者血清中MASP-2的浓度水平明显高于肺部良性疾病患者和健康人,差异有显著统计学意义(Z=2.942,P<0.01);联合检测MASP-2和Cyfra21-1在NSCLC中的灵敏度为64.0%,显著高于单一肿瘤标志物的阳性率(χ~2=7.714,P<0.01);血清MASP-2在Ⅰ期和Ⅱ期NSCLC中检测的灵敏度为38.5%,显著高于Cyfra21-1(χ~2=6.212,P<0.05)。结论血清MASP-2在NSCLC的辅助诊断中具有较好的临床应用价值,联合MASP-2和Cyfra21-1可以提高NSCLC检测的灵敏度。Objective To evaluate the clinical value of serum mannan-bingding lectin associated serine protease(MASP)-2 in non-small cell lung cancer(NSCLC) patients. Methods The serum levels of MASP-2 and Cyfra21-1 in 139 NSCLC patients, 46 patients with respiratory infection of the lung and 61 healthy controls were detected by enzyme linked immunosorbent and flow fluorescence method. Results The levels of MASP-2 in NSCLC were higher than those in healthy controls and patients with respiratory infection of the lung(Z=2.942, P<0.01). The positive rate of MASP-2 combined with Cyfra21-1 in NSCLC was 64.0%, which was higher than that of single tumor marker(χ~2=7.714, P<0.01). The positive rate of MASP-2 was 38.5% in early NSCLC stages I and II, which was higher than that of Cyfra21-1(χ~2=6.212, P<0.05). Conclusion The detection of serum MASP-2 in NSCLC patients are of clinical significance in aid diagnosing NSCLC.

关 键 词：非小细胞肺癌 人甘露糖醇结合凝集素相关丝氨酸蛋白酶-2 细胞角蛋白19片段 辅助诊断 

分 类 号：R734.2[医药卫生—肿瘤]